Current filters:

Men's HealthVitaros

Apricus expands Vitaros deal with Novartis unit

Apricus expands Vitaros deal with Novartis unit


USA-based Apricus Biosciences has expanded its exclusive license agreement with Hexal AG, an affiliate…

Apricus BioscienceEuropeLicensingMen's HealthNovartisPharmaceuticalSandozVitaros

Majorelle to market Apricus’ ED product in France, Monaco and certain African countries


USA-based Apricus Biosciences has signed an exclusive license agreement with Laboratoires Majorelle,…

Apricus BioscienceEuropeLaboratoires MajorelleLicensingMen's HealthPharmaceuticalRest of the WorldVitaros

Apricus ED drug gains national phase approval in Germany


Germany's Federal Institute for Drugs and Medical Devices has granted national phase approval for USA-based…

Apricus BioscienceEuropeMen's HealthPharmaceuticalRegulationSandozVitaros

Swiss regulator stalls approval of Apricus Biosciences' Vitaros


USA-based Apricus Biosciences (Nasdaq: APRI) says that Swissmedic, the Agency for Therapeutic Products…

Apricus BioscienceEuropeMen's HealthPharmaceuticalRegulationVitaros

Apricus Biosciences gains two more approvals for ED drug Vitaros


USA-based Apricus Biosciences (Nasdaq: APRI) says that the Irish Medicines Board and the Netherlands'…

Apricus BioscienceEuropeMen's HealthPharmaceuticalRegulationReproductiveVitaros

Apricus collaborates with Sandoz for ED drug


San Diego, USA-based Apricus Biosciences (Nasdaq: APRI) said yesterday that its wholly-owned subsidiary…

Apricus BioscienceEuropeLicensingMen's HealthNovartisPharmaceuticalReproductiveSandozVitaros

Back to top